Back

Neighborhood Deprivation and Racial Disparities in Metastatic Prostate Cancer at Diagnosis: A Population-Based Study in Ohio

Payne, J. Y.; Rhodes, S.; Shoag, J.; Rothberg, M.; Le, P.; Cullen, J.; Hartman, H.

2026-06-03 epidemiology
10.64898/2026.06.02.26354723 medRxiv
Show abstract

Background: Prostate cancer survival varies by stage at diagnosis, and Black men experience a disproportionate burden of advanced disease. We examined whether neighborhood deprivation, measured by Area Deprivation Index (ADI), contributes to racial differences in metastatic presentation. Methods: We conducted a population-based study of men diagnosed with prostate cancer in the Ohio Cancer Incidence Surveillance System from 1996 to 2016. The primary endpoint was distant-stage disease at diagnosis. Generalized additive models assessed nonlinear associations of ADI and diagnosis year with metastatic risk. Inverse probability of treatment weighting (IPTW) models estimated odds ratios comparing Black with White men after sequential adjustment for diagnosis year, age, insurance, and ADI. Results: Among 135,095 men, 18,690 were Black and 116,405 were White. Distant-stage disease occurred in 7.0% of Black men and 5.0% of White men. Black men had higher median ADI (60.9 vs. 47.3). Medicaid-insured men had the highest unadjusted odds of metastatic presentation (OR, 4.68; 95% CI, 4.13-5.31), exceeding uninsured men (OR, 2.91; 95% CI, 2.54-3.34). In IPTW models without age adjustment, the odds ratio decreased from 1.54 to 1.24 after adding insurance and ADI. In age-adjusted IPTW models, the odds ratio decreased from 1.79 to 1.41 after adding insurance and ADI. Generalized additive models showed increasing metastatic risk at higher ADI values and after 2008. Conclusions: Neighborhood deprivation and insurance-related access explained part, but not all, of the excess odds of metastatic diagnosis among Black men. Impact: Integrating ADI into cancer surveillance may improve identification of populations at risk for late-stage diagnosis.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
International Journal of Cancer
42 papers in training set
Top 0.1%
12.4%
2
Scientific Reports
3102 papers in training set
Top 6%
10.1%
3
Cancer Epidemiology, Biomarkers & Prevention
17 papers in training set
Top 0.1%
8.4%
4
PLOS ONE
4510 papers in training set
Top 25%
6.8%
5
American Journal of Epidemiology
57 papers in training set
Top 0.1%
6.4%
6
JNCI: Journal of the National Cancer Institute
16 papers in training set
Top 0.1%
6.4%
50% of probability mass above
7
eLife
5422 papers in training set
Top 24%
3.7%
8
Annals of Internal Medicine
27 papers in training set
Top 0.2%
2.6%
9
Clinical Infectious Diseases
231 papers in training set
Top 2%
2.6%
10
JAMA Network Open
127 papers in training set
Top 2%
1.8%
11
PLOS Medicine
98 papers in training set
Top 2%
1.8%
12
British Journal of Cancer
42 papers in training set
Top 0.8%
1.8%
13
Epidemiology
26 papers in training set
Top 0.3%
1.7%
14
Nature Communications
4913 papers in training set
Top 52%
1.7%
15
BMC Medicine
163 papers in training set
Top 5%
1.2%
16
BMC Public Health
147 papers in training set
Top 4%
1.2%
17
The Journal of Infectious Diseases
182 papers in training set
Top 4%
0.9%
18
The Lancet Public Health
20 papers in training set
Top 0.5%
0.9%
19
Cancers
200 papers in training set
Top 4%
0.8%
20
Cureus
67 papers in training set
Top 5%
0.7%
21
Annals of Epidemiology
19 papers in training set
Top 0.6%
0.7%
22
Annals of Oncology
13 papers in training set
Top 1.0%
0.7%
23
American Journal of Preventive Medicine
11 papers in training set
Top 0.5%
0.7%
24
JMIR Public Health and Surveillance
45 papers in training set
Top 4%
0.7%
25
JNCI Cancer Spectrum
10 papers in training set
Top 0.5%
0.7%
26
The Prostate
11 papers in training set
Top 0.1%
0.7%
27
International Journal of Environmental Research and Public Health
124 papers in training set
Top 7%
0.7%
28
JAIDS Journal of Acquired Immune Deficiency Syndromes
19 papers in training set
Top 0.4%
0.7%
29
Frontiers in Medicine
113 papers in training set
Top 7%
0.7%
30
Clinical Cancer Research
58 papers in training set
Top 2%
0.6%